BIO-11006 is under clinical development by BioMarck Pharmaceuticals and currently in Phase II for Chronic Obstructive Pulmonary Disease (COPD). According to GlobalData, Phase II drugs for Chronic Obstructive Pulmonary Disease (COPD) have a 25% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how BIO-11006’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
BIO-11006 is under development for the treatment of chronic obstructive pulmonary disease (COPD), acute respiratory distress syndrome, non-small cell lung cancer, pediatric solid tumors, pyoderma gangrenosum and coronavirus disease 2019 caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), uveitis, recurrent osteosarcoma, skin inflammation, atopic dermatitis, psoriasis and Ewing's sarcoma. The drug candidate is administered as an aerosolized inhalational solution. The drug candidate is a crystalline, small soluble peptide with ten amino acids. It targets myristoylated alanine-rich C-kinase substrate (MARCKS) protein. It is derived from the N-terminal peptide of MARCKS protein. The drug candidate is based on drug and disease target identification technology.
BioMarck Pharmaceuticals overview
BioMarck Pharmaceuticals (BioMarck ) is a biopharmaceutical company that utilizes anti-MARCKS peptides for developing and licensing products targeted at difficult to treat diseases.
For a complete picture of BIO-11006’s drug-specific PTSR and LoA scores, buy the report here.